{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:33:28Z","timestamp":1768894408517,"version":"3.49.0"},"reference-count":23,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Health Commission of Hubei Province Scientific Research Project","award":["WJ2019F007"],"award-info":[{"award-number":["WJ2019F007"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The present study aimed to establish population pharmacokinetic models of latamoxef, as well as its R- and S-epimers, and generate findings to guide the individualized administration of latamoxef in pediatric patients. A total of 145 in-hospital children aged 0.08\u201310.58 years old were included in this study. Three population pharmacokinetic models of latamoxef and its R- and S-epimers were established. The stability and predictive ability of the final models were evaluated by utilizing goodness-of-fit plots, nonparametric bootstrapping, and normalized prediction distribution errors. The final model of total latamoxef was considered as a basis for the dosing regimen. A two-compartment model with first-order elimination best described the pharmacokinetics of total latamoxef. The population typical values of total latamoxef were as follows: central compartment distribution volume (V1) of 4.84 L, peripheral compartment distribution volume (V2) of 16.18 L, clearance (CL) of 1.00 L\/h, and inter-compartmental clearance (Q) of 0.97 L\/h. Moreover, R-epimer has a higher apparent volume of distribution and lower clearance than S-epimer. Body surface area (BSA) was identified as the most significant covariate to V, CL, and Q. Specific recommendations are given for dosage adjustment in pediatric patients based on BSA. This study highlights that a BSA-normalized dose of latamoxef was required when treating different bacteria to reach the therapeutic target more effectively.<\/jats:p>","DOI":"10.3390\/pharmaceutics14051033","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T05:10:32Z","timestamp":1652332232000},"page":"1033","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Population Pharmacokinetics and Dosing Regimen Optimization of Latamoxef in Chinese Children"],"prefix":"10.3390","volume":"14","author":[{"given":"Yang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanlan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinlin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sichan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuliu","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yali","family":"Tuo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1128\/AAC.20.1.30","article-title":"Epimers of moxalactam: In vitro comparison of activity and stability","volume":"20","author":"Wise","year":"1981","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_2","first-page":"1459","article-title":"The activity of moxalactam against Enterobacteriaceae and anaerobia in vitro","volume":"96","author":"Quan","year":"2016","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref_3","unstructured":"Clinical and Laboratory Standards Institute (2016). Performance Standards for Antimicrobial Susceptibility Testing: M100S, Clinical and Laboratory Standards Institute. [26th ed.]."},{"key":"ref_4","first-page":"109","article-title":"Potent antibacterial activities of latamoxef (moxalactam) against ESBL producing Enterobacteriaceae analyzed by Monte Carlo simulation","volume":"67","author":"Ito","year":"2014","journal-title":"Jpn. J. Antibiot."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/infdis\/145.3.365","article-title":"Pharmacokinetics of moxalactam in patients with normal and impaired renal function","volume":"145","author":"Aronoff","year":"1982","journal-title":"J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1128\/AAC.19.3.461","article-title":"Pharmacokinetics of moxalactam in patients with renal insufficiency","volume":"19","author":"Lam","year":"1981","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1128\/AAC.20.2.231","article-title":"Biliary excretion of moxalactam","volume":"20","author":"Martinez","year":"1981","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/clpt.1982.71","article-title":"Moxalactam epimer kinetics in children","volume":"31","author":"Nahata","year":"1982","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000457446","article-title":"Pharmacokinetic and clinical evaluation of moxalactam in infants and children","volume":"3","author":"Latif","year":"1981","journal-title":"Dev. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"635517","DOI":"10.3389\/fphar.2021.635517","article-title":"Latamoxef for Neonates with Early-Onset Neonatal Sepsis: A Study Protocol for a Randomized Controlled Trial","volume":"12","author":"Qi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/jcph.1650","article-title":"Nonparametric Methods in Population Pharmacokinetics","volume":"62","author":"Goutelle","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jcph.1633","article-title":"Parametric Approaches in Population Pharmacokinetics","volume":"62","author":"Guidi","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ijantimicag.2018.11.017","article-title":"Population pharmacokinetics and dosing optimization of latamoxef in neonates and young infants","volume":"53","author":"Qi","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: Defining antibiotic levels in intensive care unit patients: Are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jps.2600700130","article-title":"Plasma protein binding and urinary excretion of R- and S-epimers of an arylmalonylamino 1-oxacephem. I: In humans","volume":"70","author":"Yamada","year":"1981","journal-title":"J. Pharm. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1128\/AAC.24.3.383","article-title":"Developmental pharmacokinetics of moxalactam","volume":"24","author":"Reed","year":"1983","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1128\/AAC.20.5.567","article-title":"Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime","volume":"20","author":"Blaser","year":"1981","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/infdis\/122.Supplement_1.S1","article-title":"Carbenicillin: Chemistry and mode of action","volume":"122","author":"Butler","year":"1970","journal-title":"J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1021\/jm00281a005","article-title":"Semisynthetic -lactam antibiotics. 2. Synthesis and properties of D- and L- -sulfobenzylpenicillins","volume":"15","author":"Morimoto","year":"1972","journal-title":"J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13318-011-0064-7","article-title":"Pharmacokinetic differences between the epimers of cefotetan disodium after single intravenous injection in healthy Chinese volunteers","volume":"36","author":"Su","year":"2011","journal-title":"Eur. J. Drug. Metab. Pharmacokinet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/jps.2600740118","article-title":"Epimerization kinetics of moxalactam, its derivatives, and carbenicillin in aqueous solution","volume":"74","author":"Hashimoto","year":"1985","journal-title":"J. Pharm. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1023\/A:1015815321570","article-title":"Epimerization kinetics of moxalactam in frozen urine and plasma samples","volume":"7","author":"Hashimoto","year":"1990","journal-title":"Pharm. Res."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/5\/1033\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:09:05Z","timestamp":1760137745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/5\/1033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["pharmaceutics14051033"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14051033","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]}}}